ALT - Altimmune, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Altimmune, Inc.

910 Clopper Road
Suite 201S
Gaithersburg, MD 20878
United States

Full Time Employees27

Key Executives

NameTitlePayExercisedYear Born
Dr. Mitchel B. SayareExec. Chairman165.42kN/A1948
Dr. Vipin K. GargPres, CEO & Director143.62kN/A1958
Mr. William Michael BrownCFO & Principal Accounting Officer216kN/A1982
Dr. Sybil TaskerConsultant529.63kN/A1963
Mr. Bertrand Georges Ph.D.Chief Technology OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, discovers and develops immunotherapies and vaccines to address the unmet medical needs. The company develops HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus that completed the Phase I clinical trial; NasoVAX, an intranasally administered recombinant influenza vaccine that completed Phase 2a clinical trials; and NasoShield, an anthrax vaccine for protection after a single intranasal administration that is in Phase I clinical trial. Its preclinical stage products include ALT-702, a tumor immunostimulant product candidate for treating cancer; and ALT-801, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

Corporate Governance

Altimmune, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.